Advantigen Biosciences Limited Liability Company

Advantigen Biosciences Limited Liability Company, based in Oregon, WI, is at the forefront of developing next-generation immunotherapies, particularly focusing on sialic acid-binding immunoglobulin-like lectin 5 (Siglec5) as a novel target for cancer immunotherapy. The company leverages its expertise in monoclonal antibodies and near-infrared identification and detection to create advanced therapeutics and complementary biomarkers, enhancing patient selection and stratification in clinical settings.

Founded by a team of seasoned professionals, including experts in microbiology, immunology, and oncology, Advantigen Biosciences is committed to addressing various cancer types, including solid tumors and blood cancers. With a robust leadership team and a network of advisors, the company aims to expand the landscape of immuno-oncology through innovative research and development initiatives.

Generated from the website